tetano
Editor, Senior Moderator
Immun Inflamm Dis
. 2024 May;12(5):e1276.
doi: 10.1002/iid3.1276. The development of anticyclic citrullinated peptide (anti-CCP) antibody following severe COVID-19
Seyed Askar Roghani[SUP] 1 2 3 [/SUP], Mohammad Dastbaz[SUP] 1 [/SUP], Ramin Lotfi[SUP] 4 5 [/SUP], Afsaneh Shamsi[SUP] 1 [/SUP], Zahra Abdan[SUP] 2 [/SUP], Rezvan Rostampour[SUP] 2 6 [/SUP], Bijan Soleymani[SUP] 3 [/SUP], Mohammad Hossein Zamanian[SUP] 2 [/SUP], Parviz Soufivand[SUP] 2 [/SUP], Mehran Pournazari[SUP] 2 [/SUP], Mahdi Taghadosi[SUP] 1 [/SUP]
Affiliations
Objectives: The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19.
Methods: The serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA).
Results: The results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01).
Conclusion: Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19.
Keywords: COVID‐19; SARS‐CoV‐2; anti‐CCP; autoantibodies (AABs); autoimmunity.
. 2024 May;12(5):e1276.
doi: 10.1002/iid3.1276. The development of anticyclic citrullinated peptide (anti-CCP) antibody following severe COVID-19
Seyed Askar Roghani[SUP] 1 2 3 [/SUP], Mohammad Dastbaz[SUP] 1 [/SUP], Ramin Lotfi[SUP] 4 5 [/SUP], Afsaneh Shamsi[SUP] 1 [/SUP], Zahra Abdan[SUP] 2 [/SUP], Rezvan Rostampour[SUP] 2 6 [/SUP], Bijan Soleymani[SUP] 3 [/SUP], Mohammad Hossein Zamanian[SUP] 2 [/SUP], Parviz Soufivand[SUP] 2 [/SUP], Mehran Pournazari[SUP] 2 [/SUP], Mahdi Taghadosi[SUP] 1 [/SUP]
Affiliations
- PMID: 38780036
- DOI: 10.1002/iid3.1276
Objectives: The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19.
Methods: The serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA).
Results: The results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01).
Conclusion: Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19.
Keywords: COVID‐19; SARS‐CoV‐2; anti‐CCP; autoantibodies (AABs); autoimmunity.